The verdictFor the next 12 months the evidence leans negative, for three reasons: The VAC deal commits $718M of the ~$937M of liquid assets, and there is no financing exit: failing to close for lack of money counts as a "Willful Breach". Neither the Donald investment decision nor a single rare-earth offtake has been signed, and the $300M ATM is used up. A share raise therefore looks more likely than not. The long-term case got…
Written by Claude (Anthropic’s AI) from public sources · Willem owns UUUU · AI can make mistakes — numbers in brackets point to the sources · Not financial advice
Bull arguments show how well they survive the devil’s advocate (strong / medium / weak); bear arguments show the damage they could do after the counter-argument (high / medium / low).
| Item | First stated | Latest |
|---|---|---|
| Donald investment decision | Q1 2026 (10-K) | Q3 2026; nothing announced by 10-13 [2,15,53] |
| Dy/Tb commercial output | Q4 2026 (Q3-25 10-Q) | Q4 2027 [4,18] |
| Phase 2 | 2028 | 2029 [4,1] |
| ASM closing | June 2026 | 2026-08-28 [14,9] |
| Vara Mada | agreement near-signed, autumn 2025 | unsigned; decision target 2027 [2,16] |
Consensus (StockAnalysis, 6–8 analysts): FY2026 revenue $132.2M and EPS −$0.28; FY2027 revenue $262.4M and EPS $0.49 [32]. Other aggregators range from $206M to $383M of FY2027 revenue (Yahoo, Fintel, Chartmill; dates and analyst counts unclear, low reliability). Whether VAC is included is not disclosed, and FY2028 consensus was not found. Because consensus is unreliable and EPS is near zero, impacts below are stated as pre-tax profit or EBITDA per share on ~330.6M post-VAC shares, and in absolute dollars.
Binding Dy/Tb offtake at ex-China pricing before the circuit starts — 35% chance by end-2027
Sumter reaches 4,000 t/yr by 2028 on DFARS defence demand — 25% chance by end-2028
Uranium term price ≥$110/lb on uncontracted pounds in 2028 — 30% chance by end-2028
A government price floor or offtake extended to Energy Fuels — 20% chance within 36 months
Vara Mada investment agreement signed — 20% chance within 36 months
Donald investment decision slips past mid-2027 or fails — 40% chance by 2027-06-30
China eases heavy-REE licensing; the ex-China Dy/Tb premium halves by 2028 — 25% chance
Equity raise of ≥$250M at ≤$12 within 24 months — 60% chance by 2028-10
VAC closing slips past 2027-03-22, or German conditions dilute the US case — 30% chance
The OSC loan arrives with warrants >5% of shares, or misses its offtake test — 35% chance by end-2027
Uranium term price below $80/lb in 2027–28 — 15% chance
| # | Factor | Weight | Measured value | Score | Why |
|---|---|---|---|---|---|
| 1 | Liquidity & funding runway | 15% | ~$937M liquid at 06-30; TTM FCF ≈ −$120M; after VAC cash ≈ $193M against ≥$265M of 2027 needs + $100M Goldman floor → ~12–18 mo post-close (estimate) | 62 | More than 36 months today, but VAC is contractually committed, so the post-close runway counts. |
| 2 | Leverage | 10% | $700M 0.75% converts (2031) + $140M VAC adjusted net debt (€450M gross) + up to $250M Goldman; group EBITDA negative (VAC adj. +$29M) | 70 | Large debt against negative EBITDA, but very cheap and nothing due within 24 months, so not 81+. |
| 3 | Dilution | 10% | +14.8% in ~13 mo (230.7M→264.8M); +65.9M VAC (+25%), 34.4M convert shares, $135M preferred, OSC warrants TBD | 82 | More than +25% including committed issuance. |
| 4 | Profitability | 10% | Q2 FCF margin −153%, TTM ≈ −115%; op margin −122% (Q2); gross margin 27.8%→57.4% over 4 qtrs | 74 | Clearly loss-making; gross margin improving. |
| 5 | Revenue quality & concentration | 10% | 99.5% uranium; top customer 26%, top 3 61%; one mill; RPO $165.9M | 58 | 20–35% band, pushed up by a single processing asset. |
| 6 | Execution & track record | 10% | Uranium guides beaten (2025); Donald investment decision missed 3 quarters; Dy/Tb +1 yr; Phase 2 +1 yr; ASM +2 mo; no material weakness | 68 | Big, repeated delays on rare-earth milestones; offset by clean controls and in-house delivery. |
| 7 | Competitive position & disruption | 10% | Only licensed dual mill; heavy REE behind MP/Lynas/Iluka; no floor; NdPr premium ~0 | 45 | Strong niche asset, but a contested and late entrant in heavies. |
| 8 | Cyclicality & commodity/macro | 10% | Revenue $0.4–0.7M in 2019–20 [58]; uranium + policy-set REE prices; mill campaigns | 72 | Two volatile commodities; no floor. |
| 9 | Regulatory, legal & geopolitical | 5% | China export regime, German FDI, Madagascar, OSC False Claims Act, licence challenges, congressional probe | 62 | Several large pending decisions, China exposure on pricing. |
| 10 | Valuation & expectations | 10% | ~$2.56B mkt cap; EV ≈ $2.3B ≈ 17x FY26 / ~9x FY27 cons revenue; P/B ~2.5x; short interest ~20–23% of float (unconfirmed date); 52-wk low | 60 | Rich on current numbers, with heavy short interest, but targets and history suggest expectations have reset. |
Overall: weighted average = 0.15×62 + 0.10×70 + 0.10×82 + 0.10×74 + 0.10×58 + 0.10×68 + 0.10×45 + 0.10×72 + 0.05×62 + 0.10×60 = 65.3 → 65. Change vs last: +3. The method changed, so this is not a like-for-like move. The new facts that pushed it up are:
Higher ex-China Dy/Tb prices and the on-time DFARS date held the competitive score down.
Ranking check: At 65 it sits between IAUX (64) and DUOT (66):